ciltacabtagene autoleucel,Idecabtagene Vicleucel
Janssen,BMS,2Seventy Bio
['caveat', 'match trial', 'cartitude-1', 'mmsm', 'karmma', 'cartitude']
just presented by at #asco23, now in ! amazing results, and excited to see car-t move into earlier lines in #mmsm. only caveat, though: no guarantee fda package insert will match trial criteria (e.g., karmma and cartitude-1 allowed 3+ prior lines but fda said 4+). 
Asst Professor @UWMedicine @fredhutch. Goal: improve pt experience in myeloma #MMsm: ⬇️ dex! ⬆️ time at home! 📱-based wellness!

COI: https://t.co/3Uuojuio6R